Increased expression of avian erythroblastosis virus E26 oncogene homolog 1 in World Health Organization Grade 1 meningiomas is associated with an elevated risk of recurrence and is correlated with the expression of its target genes matrix metalloproteinase-2 and MMP-9

Cancer

Volumn 107, Issue 6, 2006, Pages 1365-1372

  Okuducu, Ali Fuat ^a   Zils, Ulrich ^a   Michaelis, Silke A M ^a   Mawrin, Christian ^b   Von Deimling, Andreas ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Avian erythroblastosis virus E26 oncogene homolog 1; Matrix metalloproteinase; Meningioma; Prognosis; Recurrence

Indexed keywords

GELATINASE A; GELATINASE B; TRANSCRIPTION FACTOR ETS 1;

ARTICLE; AVIAN ERYTHROBLASTOSIS ONCOVIRUS; CANCER GRADING; CANCER RECURRENCE; CANCER RISK; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FOLLOW UP; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MENINGIOMA; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECURRENT CANCER; RISK FACTOR; TRANSCRIPTION REGULATION; UPREGULATION; WORLD HEALTH ORGANIZATION;

AGED; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MENINGEAL NEOPLASMS; MENINGIOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROTO-ONCOGENE PROTEIN C-ETS-1; RISK FACTORS; WORLD HEALTH ORGANIZATION;

EID: 33749000297     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22130     Document Type: Article

References (43)

1. Louis DN, Scheithauer BW, Budka H, von Deimling A, Kepes JJ. Meningiomas. In: Kleihues P, Cavenee WK, editors. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Nervous System. Lyon: IARC Press; 2000:174-186.
2. Abramovich CM, Prayson RA. Histopathologic features and MIB-1 labeling indices in recurrent and nonrecurrent meningiomas. Arch Pathol Lab Med. 1999;123:793-800.
3. Bouvier C, Liprandi A, Colin C, et al. Lack of alkaline phosphatase activity predicts meningioma recurrence. Am J Clin Pathol. 2005;124:252-258.
4. Maes L, Lippens E, Kalala JP, de Ridder L. The hTERT-protein and Ki-67 labelling index in recurrent and non-recurrent meningiomas. Cell Prolif. 2005;38:3-12.
5. Martinez-Rumayor A, Arrieta O, Guevara P, et al. Coexpression of hepatocyte growth factor/scatter factor (HGF/SF) and its receptor cMET predict recurrence of meningiomas. Cancer Lett. 2004;213:117-124.
6. Paek SH, Kim CY, Kim YY, et al. Correlation of clinical and biological parameters with peritumoral edema in meningioma. J Neurooncol. 2002;60:235-245.
7. Nordqvist AC, Smurawa H, Mathiesen T. Expression of matrix metalloproteinases 2 and 9 in meningiomas associated with different degrees of brain invasiveness and edema. J Neurosurg. 2001;95:839-844.
8. Kachra Z, Beaulieu E, Delbecchi L, et al. Expression of matrix metalloproteinases and their inhibitors in human brain tumors. Clin Exp Metastasis. 1999;17:555-566.
9. Perret AG, Duthel R, Fotso MJ, Brunon J, Mosnier JF. Stromelysin-3 is expressed by aggressive meningiomas. Cancer. 2002;94:765-772.
10. Stamenkovic I. Extracellular matrix remodelling: the role of matrix metalloproteinases. J Pathol. 2003;200:448-464.
11. Folgueras AR, Pendas AM, Sanchez LM, Lopez-Otin C. Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. Int J Dev Biol. 2004;48:411-424.
12. Kamitani H, Masuzawa H, Kanazawa I, Kubo T. Recurrence of convexity meningiomas: tumor cells in the arachnoid membrane. Surg Neurol. 2001;56:228-235.
13. Ayerbe J, Lobato RD, de la Cruz J, et al. Risk factors predicting recurrence in patients operated on for intracranial meningioma. A multivariate analysis. Acta Neurochir (Wien). 1999;141:921-932.
14. Michaelis SA, Okuducu AF, Sarioglu NM, von Deimling A, Dudenhausen JW. The transcription factor Ets-1 is expressed in human amniochorionic membranes and is up-regulated in term and preterm premature rupture of membranes. J Perinat Med. 2005;33:314-319.
15. Dittmer J. The biology of the Ets1 proto-oncogene. Mol Cancer. 2003;2:29. Abstract.
16. Sementchenko VI, Watson DK. Ets target genes: past, present and future. Oncogene. 2000;19:6533-6548.
17. Sharrocks AD. The ETS-domain transcription factor family. Nat Rev Mol Cell Biol. 2001;2:827-837.
18. Trojanowska M. Ets factors and regulation of the extracellular matrix. Oncogene. 2000;19:6464-6471.
19. Lionneton F, Drobecq H, Soncin F. Expression and purification of recombinant mouse Ets-1 transcription factor. Protein Expr Purif. 2001;21:492-499.
20. Fujimoto N, Mouri N, Iwata K, Ohuchi E, Okada Y, Hayakawa T. A one-step sandwich enzyme immunoassay for human matrix metalloproteinase 2 (72-kDa gelatinase/Type IV collagenase) using monoclonal antibodies. Clin Chim Acta. 1993;221:91-103.
21. Ramos-DeSimone N, Moll UM, Quigley JP, French DL. Inhibition of matrix metalloproteinase 9 activation by a specific monoclonal antibody. Hybridoma. 1993;12:349-363.
22. Reiner A, Spona J, Reiner G, et al. Estrogen receptor analysis on biopsies and fine-needle aspirates from human breast carcinoma. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Am J Pathol. 1986;125:443-449.
23. Davidson B, Risberg B, Goldberg I, et al. Ets-1 mRNA expression in effusions of serous ovarian carcinoma patients is a marker of poor outcome. Am J Surg Pathol. 2001;25:1493-1500.
24. Saeki H, Kuwano H, Kawaguchi H, Ohno S, Sugimachi K. Expression of ets-1 transcription factor is correlated with penetrating tumor progression in patients with squamous cell carcinoma of the esophagus. Cancer. 2000;89:1670-1676.
25. Nakayama T, Ito M, Ohtsuru A, Naito S, Sekine I. Expression of the ets-1 proto-oncogene in human colorectal carcinoma. Mod Pathol 2001;14:415-422.
26. Sato T, Miwa A. Ets-1 and integrin beta3 for lung metastasis from colorectal cancer. APMIS. 2002;110:347-353.
27. Sahin A, Velten M, Pietsch T, et al. Inactivation of Ets 1 transcription factor by a specific decoy strategy reduces rat C6 glioma cell proliferation and mmp-9 expression. Int J Mol Med. 2005;15:771-776.
28. Hahne JC, Okuducu AF, Kaminski A, Florin A, Soncin F, Wernert N. Ets-1 expression promotes epithelial cell transformation by inducing migration, invasion and anchorage-independent growth. Oncogene. 2005;24:5384-5388.
29. Kitange G, Tsunoda K, Anda T, et al. Immunohistochemical expression of Ets-1 transcription factor and the urokinase-type plasminogen activator is correlated with the malignant and invasive potential in meningiomas. Cancer. 2000;89:2292-2300.
30. Bachmeier BE, Rohrbach H, De Waal J, Jochum M, Nerlich AG. Enhanced expression and activation of major matrix metalloproteinases in distinct topographic areas of invasive breast carcinomas. Int J Oncol. 2005;26:1203-1207.
31. Horiuchi S, Yamamoto H, Min Y, Adachi Y, Itoh F, Imai K. Association of ets-related transcriptional factor E1AF expression with tumour progression and overexpression of MMP-1 and matrilysin in human colorectal cancer. J Pathol. 2003;200:568-576.
32. Sasaki H, Yukiue H, Moiriyama S, et al. Clinical significance of matrix metalloproteinase-7 and Ets-1 gene expression in patients with lung cancer. J Surg Res. 2001;101:242-247.
33. Thorns V, Walter GF, Thorns C. Expression of MMP-2, MMP-7, MMP-9, MMP-10 and MMP-11 in human astrocytic and oligodendroglial gliomas. Anticancer Res. 2003;23:3937-3944.
34. Jaalinoja J, Herva R, Korpela M, Hoyhtya M, Turpeenniemi-Hujanen T. Matrix metalloproteinase 2 (MMP-2) immunoreactive protein is associated with poor grade and survival in brain neoplasms. J Neurooncol 2000;46:81-90.
35. Okada M, Miyake K, Matsumoto Y, Kawai N, Kunishio K, Nagao S. Matrix metalloproteinase-2 and matrix metalloproteinase-9 expressions correlate with the recurrence of intracranial meningiomas. J Neurooncol. 2004;66:29-37.
36. Das A, Tan WL, Smith DR. Expression of extracellular matrix markers in benign meningiomas. Neuropathology. 2003;23:275-281.
37. Behrens P, Rothe M, Florin A, Wellmann A, Wernert N. Invasive properties of serous human epithelial ovarian tumors are related to Ets-1, MMP-1 and MMP-9 expression. Int J Mol Med. 2001;8:149-154.
38. Behrens P, Rothe M, Wellmann A, Krischler J, Wernert N. The Ets-1 transcription factor is up-regulated together with MMP 1 and MMP 9 in the stroma of pre-invasive breast cancer. J Pathol. 2001;194:43-50.
39. Ozaki I, Mizuta T, Zhao G, et al. Involvement of the Ets-1 gene in overexpression of matrilysin in human hepatocellular carcinoma. Cancer Res. 2000;60:6519-6525.
40. Jung HW, Yoo H, Paek SH, Choi KS. Long-term outcome and growth rate of subtotally resected petroclival meningiomas: experience with 38 cases. Neurosurgery. 2000;46:567-574; discussion, 574-565.
41. Little KM, Friedman AH, Sampson JH, Wanibuchi M, Fukushima T. Surgical management of petroclival meningiomas: defining resection goals based on risk of neurological morbidity and tumor recurrence rates in 137 patients. Neurosurgery. 2005;56:546-559; discussion, 546-559.
42. Couldwell WT, Fukushima T, Giannotta SL, Weiss MH. Petroclival meningiomas: surgical experience in 109 cases. J Neurosurg. 1996;84:20-28.
43. Lobato RD, Gonzaaez P, Alday R, et al. Meningiomas of the basal posterior fossa. Surgical experience in 80 cases. Neurocirugia (Astur). 2004;15:525-542.